Features | Partner Sites | Information | LinkXpress
Sign In
Shuenn Bao Shing Corporation
Samsung
SOREDEX

Mesh Matrix Treats Hard-to-Heal Wounds

By HospiMedica International staff writers
Posted on 27 Feb 2014
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
Image: The MatriStem Multilayer Wound Matrix device is designed for deep, hard-to-heal wounds (Photo courtesy of ACell).
A new multilayer matrix device accommodates moderate to heavy wound exudate and provides effective contouring functionality in wound treatment.

The MatriStem Multilayer Wound Matrix device is designed to maintain and support a healing environment through constructive tissue remodeling for both acute and chronic wounds. The device is comprised of naturally occurring urinary bladder matrix (UBM), the basement membrane of porcine urinary bladder tissue, which is disinfected, packaged, and sterilized to produce a non-cross-linked, completely resorbable, acellular extracellular matrix (ECM) scaffold that is rich with naturally occurring collagens and proteins.

UBM provides several distinguishable characteristics, including the recruitment of progenitor cells, chemotactic and mitogenic activities, and site-specific tissue remodeling. UBM also has the ability to facilitate the body’s own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two-year shelf life; and superior ease-of-use characteristics.

MatriStem is easy to prepare, apply, and fixate, and requires no special handling requirements. It is indicated for all types of wound management, including pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological, and gastroenterological anatomy. The MatriStem Multilayer Wound Matrix device is a product of ACell (Columbia, MD, USA), and has been approved by the US Food and Drug Administration (FDA).

“ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management,” said Jim DeFrancesco, CEO of ACell. “The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds.”

Related Links:

ACell



Dunlee
Anetic Aid
CardioComm Solutions

Channels

Critical Care

view channel
Image: Solid microneedles coated with Bevacizumab (syringe for scale) (Photo courtesy of the Georgia Institute of Technology).

Tiny Needles Reshape Major Eye Disease Treatment

Novel microneedles allow dramatic dose sparing when compared to subconjunctival and topical administration of drugs directly into the eye. Developed by researchers at the Georgia Institute of Technology... Read more

Women's Health

view channel

Women with PTSD Face Higher Pregnancy Risk

Suffering from post-traumatic stress disorder (PTSD) significantly increases a pregnant woman's risk of premature birth, according to a new study. Researchers at Stanford University (CA, USA) conducted a study to identify antenatal PTSD status and spontaneous preterm delivery in a retrospective cohort (2000-2012).... Read more

Business

view channel

Global Wound Care Market Rife With Opportunity

Strong relationships with end users and an effective post sales service strategy must be a priority for wound care companies. These are the latest findings of Frost & Sullivan (Frost; London, United Kingdom), an international market research firm. The global wound care market is at a growth stage, driven by the increasingly... Read more
 

Events

26 Nov 2014 - 28 Nov 2014
01 Dec 2014 - 05 Dec 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.